Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

4.130 -0.290 (-6.56%)
Streaming Delayed Price Updated: 1:40 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,411
Open 4.110
Bid (Size) 4.120 (100)
Ask (Size) 4.210 (100)
Prev. Close 4.420
Today's Range 4.030 - 4.217
52wk Range 1.327 - 5.480
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
From Cellectis Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline. 
Via The Motley Fool

Performance

YTD
-14.0%
-14.0%
1 Month
+23.7%
+23.7%
3 Month
-0.5%
-0.5%
6 Month
+4.6%
+4.6%
1 Year
+199.3%
+199.3%

More News

Read More
News headline image
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Earnings Preview ↗
Via Benzinga
News headline image
Cellectis Announces 2026 Strategy and Catalysts
From Cellectis Inc.
Via GlobeNewswire
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Arbitral Decision in Dispute with Servier
From Cellectis Inc.
Via GlobeNewswire
News headline image
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
From Cellectis Inc.
Via GlobeNewswire
News headline image
Why Cellectis Stock Is Trading Higher Today ↗
Via Benzinga
News headline image
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
From Cellectis Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 7, 2025 ↗
Via Benzinga
News headline image
Cellectis to Present a Development Update for eti-cel at ASH 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report Third Quarter Financial Results on November 7, 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
From Cellectis Inc.
Via GlobeNewswire
News headline image
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday ↗
Via Benzinga
News headline image
Top 2 Health Care Stocks That May Keep You Up At Night This Month ↗
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
From Cellectis Inc.
Via GlobeNewswire
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill

Frequently Asked Questions

Is Cellectis S.A. - American Depositary Shares publicly traded?
Yes, Cellectis S.A. - American Depositary Shares is publicly traded.
What exchange does Cellectis S.A. - American Depositary Shares trade on?
Cellectis S.A. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectis S.A. - American Depositary Shares?
The ticker symbol for Cellectis S.A. - American Depositary Shares is CLLS on the Nasdaq Stock Market
What is the current price of Cellectis S.A. - American Depositary Shares?
The current price of Cellectis S.A. - American Depositary Shares is 4.130
When was Cellectis S.A. - American Depositary Shares last traded?
The last trade of Cellectis S.A. - American Depositary Shares was at 04/20/26 01:40 PM ET
What is the market capitalization of Cellectis S.A. - American Depositary Shares?
The market capitalization of Cellectis S.A. - American Depositary Shares is 187.86M
How many shares of Cellectis S.A. - American Depositary Shares are outstanding?
Cellectis S.A. - American Depositary Shares has 188M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.